Research Analysts Set Expectations for BCAX FY2025 Earnings

Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Stock analysts at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of Bicara Therapeutics in a report released on Monday, March 31st. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will post earnings of ($1.81) per share for the year, up from their previous forecast of ($2.50). Cantor Fitzgerald currently has a "Overweight" rating and a $13.01 target price on the stock. The consensus estimate for Bicara Therapeutics' current full-year earnings is ($2.59) per share.

Other equities analysts also recently issued research reports about the company. Wedbush reaffirmed an "outperform" rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Stifel Nicolaus set a $48.00 target price on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Finally, HC Wainwright raised their price target on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a "buy" rating in a research report on Monday, January 27th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $36.67.

Bicara Therapeutics Trading Down 10.7 %

BCAX stock traded down $1.26 during midday trading on Wednesday, reaching $10.57. 511,870 shares of the company were exchanged, compared to its average volume of 469,933. The business has a 50-day moving average price of $13.07 and a two-hundred day moving average price of $17.52. Bicara Therapeutics has a one year low of $10.52 and a one year high of $28.09.

Remove Ads

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.08).

Institutional Investors Weigh In On Bicara Therapeutics

Large investors have recently bought and sold shares of the company. California State Teachers Retirement System bought a new stake in shares of Bicara Therapeutics during the 4th quarter worth approximately $25,000. Spire Wealth Management acquired a new position in Bicara Therapeutics during the fourth quarter valued at approximately $31,000. BNP Paribas Financial Markets bought a new stake in Bicara Therapeutics during the fourth quarter worth $32,000. Legal & General Group Plc acquired a new stake in shares of Bicara Therapeutics in the 4th quarter valued at $33,000. Finally, Summit Investment Advisors Inc. bought a new position in shares of Bicara Therapeutics in the 4th quarter valued at $35,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.